尼可地尔骨架型缓释片的处方优化及体外释药研究
x

请在关注微信后,向客服人员索取文件

篇名: 尼可地尔骨架型缓释片的处方优化及体外释药研究
TITLE:
摘要: 目的:优化尼可地尔骨架型缓释片的处方,评价其体外释药特性。方法:采用粉末直接压片法,在单因素考察的基础上,以1、4、8、12 h尼可地尔的累积释放度(Q)为评价指标,用星点设计-响应面法优化制剂辅料中羟丙甲基纤维素(HPMC)、乙基纤维素(EC)的用量;比较所制缓释片在不同pH(1.0、5.0、6.8、7.4)介质中12 h内的Q值。结果:最优处方(每片量)为尼可地尔10 mg、HPMC 150 mg、EC 90 mg、微晶纤维素80 mg、乳糖60 mg、硬脂酸镁2%;所制缓释片的Q1 h、Q4 h、Q8 h、Q12 h分别为23.6%、51.3%、83.7%、96.9%,与预测值的偏差分别为2.1%、1.6%、1.0%、0.2%;缓释片在pH 1.0~7.4的介质中各时间点的Q值相近。结论:优化处方所制的尼可地尔骨架型缓释片具有缓释作用,pH在1.0~7.4范围内变化对其主药的释放无干扰。
ABSTRACT: OBJECTIVE: To optimize the formulation optimization of Nicorandil sustained-release matrix tablet, and evaluate its drug release properties in vitro. METHODS: Based on single factor test, powder direct compression method was used, using nicorandil cumulative release rate (Q) in 1, 4, 8, 12 h as evaluation indexes, central composite design-response surface method was adopted to optimize the amount of hydroxypropyl methylcellulose (HPMC) and ethyl cellulose (EC); Q values within 12 h in different pH (1.0, 5.0, 6.8, 7.4) media were compared. RESULTS: The optimized formulation (every tablet) was nicorandil 10 mg, HPMC 150 mg, EC 90 mg, microcrystalline cellulose 80 mg, lactose 60 mg, magnesium stearate 2%. Q1 h, Q4 h, Q8 h and Q12 h of the obtained formulation were 23.6%, 51.3%, 83.7% and 96.9%, respectively; deviation from the predicted values were 2.1%, 1.6%, 1.0%, 0.2%. Q values were similar in pH 1.0-7.4 at different time points. CONCLUSIONS: The obtained Nicorandil sustained-release matrix tablet by optimal formulation shows sustained-release effect, and the change of pH 1.0-7.4 has no interference in the release characteristics of main drug.
期刊: 2016年第27卷第25期
作者: 金桂兰,罗平,杜娟,林宁,谭建玲,邢翔飞
AUTHORS: JIN Guilan,LUO Ping,DU Juan,LIN Ning,TAN Jianling,XING Xiangfei
关键字: 尼可地尔;骨架型缓释片;处方优化;星点设计-响应面法;体外释药
KEYWORDS: Nicorandil; Sustained-release matrix tablet; Formulation optimization; Central composite design-response surface method; Drug release in vitro
阅读数: 407 次
本月下载数: 6 次

* 注:未经本站明确许可,任何网站不得非法盗链资源下载连接及抄袭本站原创内容资源!在此感谢您的支持与合作!